secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001213900-26-054019
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics CEO to present at Precision Medicine Forum Europe 2026
----------------------------------------------------------------------------

- CEO Thomas Jensen will speak on May 11, 2026, in Stockholm, Sweden at Precision Medicine Forum Europe 2026.
- Presentation will cover stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and the Stenoparib DRP biomarker.
- Allarity is a Phase 2 clinical-stage company developing stenoparib for cancer; no new clinical data or financial results announced.
- A corporate presentation furnished as Exhibit 99.1 will be used in investor meetings beginning May 11, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026054019/0001213900-26-054019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026054019/ea0289893-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-054019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer